TAP
REGN icon

Tounjian Advisory Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Tounjian Advisory Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,026
Closed -$651K – 221
2025
Q2 		$651K Sell
1,026
-16
-2% -$8.93K 0.13% 172
2025
Q1 		$662K Buy
+1,042
New +$717K 0.12% 173

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tounjian Advisory Partners's REGN Position: Q3 2025 in Review

Tounjian Advisory Partners sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 1,026 shares — an estimated $651K sold.

Tounjian Advisory Partners first reported a position in REGN in Q1 2025 and held it in 2 quarters. The position peaked at $662K in Q1 2025. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Tounjian Advisory Partners reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Tounjian Advisory Partners sold 1,026 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $651K.
  • Tounjian Advisory Partners first reported a position in Regeneron Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Tounjian Advisory Partners's Regeneron Pharmaceuticals position peaked at $662K in Q1 2025.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Tounjian Advisory Partners's 13F filing for Q3 2025, filed 12 Nov 2025.